Gerard Evan

Gerard Evan
Born (1955-08-17) 17 August 1955 (age 69)[10]
Alma materSt Peter's College, Oxford
King's College, Cambridge[10]
Known forDisease Models & Mechanisms
AwardsFellow of the Royal Society (2004)
FMedSci (1999)[1]
PhD (1982)
Scientific career
FieldsCancer[2][3][4][5][6][7]
Disease biology
Myc regulator gene[8]
p53 tumour suppressor[9]
InstitutionsUniversity of Oxford
University of Cambridge
UCSF[10][11]
Cancer Research UK[12]
Ensemble Therapeutics
ThesisMonoclonal antibodies as reagents for the analysis of cell surfaces (1982)
Websitewww.bioc.cam.ac.uk/uto/evan
labmed.ucsf.edu/about/faculty/pathology-gevan.html

Gerard Ian Evan FRS, FMedSci (born 17 August 1955) is a British biologist and, since May 2022, Professor of Cancer Biology at King's College London and a principal group leader in the Francis Crick Institute. Prior to this he was Sir William Dunn Professor of Biochemistry and Head of Biochemistry at the University of Cambridge (2009-2022).[11][13]

  1. ^ http://www.acmedsci.ac.uk/p59fid5303.html [dead link]
  2. ^ Finch, A. J.; Soucek, L.; Junttila, M. R.; Swigart, L. B.; Evan, G. I. (2009). "Acute Overexpression of Myc in Intestinal Epithelium Recapitulates Some but Not All the Changes Elicited by Wnt/ -Catenin Pathway Activation". Molecular and Cellular Biology. 29 (19): 5306–5315. doi:10.1128/MCB.01745-08. PMC 2747972. PMID 19635809.
  3. ^ Garcia, D.; Warr, M. R.; Martins, C. P.; Brown Swigart, L.; Passegue, E.; Evan, G. I. (2011). "Validation of MdmX as a therapeutic target for reactivating p53 in tumors". Genes & Development. 25 (16): 1746–1757. doi:10.1101/gad.16722111. PMC 3165938. PMID 21852537.
  4. ^ Murphy, D. J.; Junttila, M. R.; Pouyet, L.; Karnezis, A.; Shchors, K.; Bui, D. A.; Brown-Swigart, L.; Johnson, L.; Evan, G. I. (2008). "Distinct Thresholds Govern Myc's Biological Output in Vivo". Cancer Cell. 14 (6): 447–457. doi:10.1016/j.ccr.2008.10.018. PMC 2723751. PMID 19061836.
  5. ^ Sodir, N. M.; Swigart, L. B.; Karnezis, A. N.; Hanahan, D.; Evan, G. I.; Soucek, L. (2011). "Endogenous Myc maintains the tumor microenvironment". Genes & Development. 25 (9): 907–916. doi:10.1101/gad.2038411. PMC 3084025. PMID 21478273.
  6. ^ Kain, K. (2008). "The future of cancer therapy: An interview with Gerard Evan". Disease Models and Mechanisms. 1 (2–3): 90–93. doi:10.1242/dmm.001396. PMC 2562192. PMID 19048069.
  7. ^ Anon (2008). "Making the paper: Gerard Evan". Nature. 455 (7213): xiii. doi:10.1038/7213xiiia. S2CID 4410691.
  8. ^ Evan, G. (2012). "Taking a Back Door to Target Myc". Science. 335 (6066): 293–294. Bibcode:2012Sci...335..293E. doi:10.1126/science.1217819. PMID 22267799. S2CID 26445434.
  9. ^ Junttila, Melissa R.; Evan, Gerard I. (2009). "P53 — a Jack of all trades but master of none". Nature Reviews Cancer. 9 (11): 821–829. doi:10.1038/nrc2728. PMID 19776747. S2CID 29250930.
  10. ^ a b c "EVAN, Prof. Gerard Ian". Who's Who 2013, A & C Black, an imprint of Bloomsbury Publishing plc, 2013; online edn, Oxford University Press.(subscription required)
  11. ^ a b "UCSF Departments of Pathology and Laboratory Medicine | About | Faculty | Gerard I. Evan, PhD, FRS, FMedSci". Archived from the original on 1 June 2013.
  12. ^ "Gerard Evan : Cancer Research UK". Archived from the original on 10 March 2014.
  13. ^ Gerard Evan publications indexed by Microsoft Academic